4.6 Article

Effects of Multivitamin Supplement on Cataract and Age-Related Macular Degeneration in a Randomized Trial of Male Physicians

Journal

OPHTHALMOLOGY
Volume 121, Issue 2, Pages 525-534

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ophtha.2013.09.038

Keywords

-

Categories

Funding

  1. National Institutes of Health
  2. DSM Nutritional Products Inc.
  3. Bristol-Meyers Squibb
  4. AstraZeneca
  5. Novartis
  6. nonprofit Aurora Foundation
  7. Tomato Products Wellness Council
  8. Cambridge Theranostics, Ltd.
  9. Veterans Administration
  10. BASF Corporation
  11. Pfizer Inc.
  12. Nutritional Products Inc.
  13. National Eye Institute [CA 097193]
  14. National Institutes of Health (Bethesda, MD) [CA 34944, CA 40360, HL 26490, HL 34595]
  15. BASF Corporation (Florham Park, NJ)

Ask authors/readers for more resources

Purpose: To test whether long-term multivitamin supplementation affects the incidence of cataract or agerelated macular degeneration (AMD) in a large cohort of men. Design: Randomized, double-blind, placebo-controlled trial. Participants: A total of 14 641 US male physicians aged <= 50 years. Intervention: Daily multivitamin or placebo. Main Outcome Measures: Incident cataract and visually significant AMD responsible for a reduction in bestcorrected visual acuity to 20/30 or worse based on self-reports confirmed by medical record review. Results: During an average of 11.2 years of treatment and follow-up, a total of 1817 cases of cataract and 281 cases of visually significant AMD were confirmed. There were 872 cataracts in the multivitamin group and 945 cataracts in the placebo group (hazard ratio [HR], 0.91; 95% confidence interval [CI], 0.83-0.99; P 0.04). For visually significant AMD, there were 152 cases in the multivitamin group and 129 cases in the placebo group (HR, 1.19; 95% CI, 0.94-1.50; P = 0.15). Conclusions: These randomized trial data from a large cohort of middle-aged and older US male physicians indicate that long-term daily multivitamin use modestly and significantly decreased the risk of cataract but had no significant effect on visually significant AMD. (C) 2014 by the American Academy of Ophthalmology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available